Cara Therapeutics Inc (CARA) concluded trading on 12/28/23 at a closing price of $0.77, with 2.27 million shares of worth about $1.75 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -73.08% during that period and on Thursday the price saw a gain of about 16.21%. Currently the company’s common shares owned by public are about 53.80M shares, out of which, 46.29M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 5 analysts are covering the CARA stock and their offered price forecasts bring an average price target of $6.10. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $11.00 and could fall to a lowest price of $1.00. The stock’s current price level is 87.38% above of average price target set by the analysts, while a rise to estimated low would result in gain of 23.0% for the stock. However, touching the estimated high of $11.00 would mean a gain of 93.0% for the stock.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 22 times over the past 12 months. They bought 194,172 shares in 5 of the transactions. In 17 selling transactions, insiders dumped 64,118 shares.
Stock saw a price change of 26.45% in past 5 days and over the past one month there was a price change of -21.48%. Year-to-date (YTD), CARA shares are showing a performance of -92.86% which decreased to -92.18% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.57 but also hit the highest price of $12.49 during that period. The average intraday trading volume for Cara Therapeutics Inc shares is 676.57K. The stock is currently trading -19.69% below its 20-day simple moving average (SMA20), while that difference is down -29.42% for SMA50 and it goes to -71.89% lower than SMA200.
Cara Therapeutics Inc (NASDAQ: CARA) currently have 53.80M outstanding shares and institutions hold larger chunk of about 52.32% of that.
The stock has a current market capitalization of $41.80M and its 3Y-monthly beta is at 0.64. It has posted earnings per share of -$2.16 in the same period. It has Quick Ratio of 4.25 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CARA, volatility over the week remained 12.59% while standing at 15.53% over the month.
Analysts are in expectations that Cara Therapeutics Inc (CARA) stock would likely to be making an EPS of $Paramount Global in the current quarter, while forecast for next quarter EPS is $15.15 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $CAVA Group, Inc. which is $Coterra Energy Inc. at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $Maplebear Inc. in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -28.43% while it is estimated to increase by 15.48% in next year.
Analysts at 5 brokerage firms have issued recommendations for the Cara Therapeutics Inc (CARA)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.40. Out of those 5 Wall Street analysts, 4 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on March 08, 2023 offering an Underperform rating for the stock and assigned a target price range of between $13 and $6 to it.
